首次与第二次缓解期接受异基因干细胞移植的急性髓系白血病患者MRD状态的影响
分析580例在首次(79%)或第二次(21%)缓解期接受异基因造血干细胞移植的急性髓系白血病患者,移植时MRD状态为独立预后因素,且不受移植时缓解次数影响。首次缓解期MRD+患者与第二次缓解期MRD-患者结局相似。在ELN2017中危组中,MRD状态预后价值最高,第二次缓解期移植的MRD+患者结局极差。
要点
- 移植时MRD状态是独立预后因素,不受移植时缓解次数影响。
- 首次缓解期MRD+与第二次缓解期MRD-患者结局相似。
- ELN2017中危组中,第二次缓解期MRD+移植患者结局极差。
核心结论
- 移植时MRD状态是独立预后因素,不受移植时缓解次数影响。
- 首次缓解期MRD+患者与第二次缓解期MRD-患者结局相似。
- 在ELN2017中危组中,MRD状态提供最高预后价值,第二次缓解期移植的MRD+患者结局极差。
- 作者认为,在制定巩固治疗计划时应考虑MRD+患者和第二次缓解期移植患者的不良结局,以尽可能避免在MRD+的第二次缓解期进行异基因造血干细胞移植。
研究设计与样本
- 分析了580例接受异基因造血干细胞移植的急性髓系白血病患者,其中首次缓解期移植占79%,第二次缓解期移植占21%。
主要发现
- 尽管第二次缓解期移植患者中单体核型或复杂核型等不良风险特征较少见,但这些患者结局仍差于首次缓解期移植患者。
- 移植时MRD状态是独立预后因素,不受移植时缓解次数影响。
- 首次缓解期MRD+患者与第二次缓解期MRD-患者结局相似。
- 在ELN2017中危组中,MRD状态预后价值最高,第二次缓解期移植的MRD+患者结局极差。
临床怎么用
- 作者认为,在制定巩固治疗计划时应考虑MRD+患者和第二次缓解期移植患者的不良结局,以尽可能避免在MRD+的第二次缓解期进行异基因造血干细胞移植。
局限性
- 原文未报告局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Allogeneic hematopoietic stem cell transplantation (HSCT) offers the best chance for relapse-free survival to most patients with acute myeloid leukemia (AML). It may be performed during complete remission or delayed until after the first relapse because of relevant treatment-related morbidity and mortality. The measurable residual disease (MRD) status at HSCT adds refined prognostic information to the assigned European LeukemiaNet (ELN) 2017 genetic risk at diagnosis. We analyzed 580 patients with AML who underwent allogeneic HSCT during either the first (79%) or second (21%) remission. Although, because of common treatment strategies, some adverse risk characteristics, such as monosomal or complex karyotypes, were less frequent in patients who underwent transplant in the second remission, those patients had worse outcomes compared with patients who had transplant in the first remission. The MRD status at HSCT was an independent prognostic factor, irrespective of the number of remissions at HSCT. Notably, patients who were MRD+ who underwent HSCT in the first remission and those who were MRD- and underwent transplant in the second remission had similar outcomes. In the clinically highly relevant group of individuals who had ELN2017 intermediate risk, the MRD status provided the highest prognostic value with very dismal outcomes for patients who were MRD+ and underwent second-remission transplants. The adverse outcomes of patients who are MRD+ and of those who undergo transplant in the second remission should be considered when planning consolidation treatment, to avert an allogeneic HSCT in MRD+ second remission when possible.
引用
- Jentzsch M, Bischof L, Backhaus D, et al. Impact of MRD status in patients with AML undergoing allogeneic stem cell transplantation in the first vs the second remission. Blood Adv. 2022. PMID: 35605254. doi:10.1182/bloodadvances.2022007168
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。